A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert C Welsh, MD
University of Alberta
Principal Investigator - Sunil V Rao, MD
Duke University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
59 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Portola Investigational Site
Graz, Austria
- Portola Investigational Site
Vienna, Austria
- Portola Investigational Site
Calgary, Alberta, Canada
- Portola Investigational Site
Edmonton, Alberta, Canada
- Portola Investigational Site
Vancouver, British Columbia, Canada
- Portola Investigational Site
St. John's, Newfoundland and Labrador, Canada
- Portola Investigational Site
Newmarket, Ontario, Canada
- Portola Investigational Site
Toronto, Ontario, Canada
- Portola Investigational Site
Bad Oeynhausen, Germany
- Portola Investigational Site
Bad Rothenfelde, Germany
- Portola Investigational Site
Berlin, Germany
- Portola Investigational Site
Bernau, Germany
- Portola Investigational Site
Dachau, Germany
- Portola Investigational Site
Dortmund, Germany
- Portola Investigational Site
Dresden, Germany
- Portola Investigational Site
Göttingen, Germany
- Portola Investigational Site
Halle, Germany
- Portola Investigational Site
Hanover, Germany
- Portola Investigational Site
Heidelberg, Germany
- Portola Investigational Site
Kassel, Germany
- Portola Investigational Site
Kiel, Germany
- Portola Investigational Site
Langen, Germany
- Portola Investigational Site
Ludwigshafen, Germany
- Portola Investigational Site
Lübeck, Germany
- Portola Investigational Site
Mainz, Germany
- Portola Investigational Site
Munich, Germany
- Portola Investigational Site
Mönchengladbach, Germany
- Portola Investigational Site
Neuss, Germany
- Portola Investigational Site
Rostock, Germany
- Portola Investigational Site
Schwalmstadt, Germany
- Portola Investigational Site
Traunstein, Germany
- Portola Investigational Site
Trier, Germany
- Portola Investigational Site
Witten, Germany
- Portola Investigational Site
Wuppertal, Germany
- Portola Investigational Site
Bydgoszcz, Poland
- Portola Investigational Site
Gdansk, Poland
- Portola Investigational Site
Lodz, Poland
- Portola Investigational Site
Lublin, Poland
- Portola Investigational Site
Szczecin, Poland
- Portola Investigational Site
Warsaw, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2008
- Primary completion
- 30 Apr 2010
- Completion
- 30 Apr 2010
- Last update posted
- 8 Aug 2023
- Registered enrollment
- 652
- Registry id
- NCT00751231
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.